CytoDyn (CYDY) has released an update to notify the public and investors about its officers.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
CytoDyn Inc. appointed Jacob P. Lalezari, M.D. as its Chief Executive Officer effective January 26, 2024, with a $400,000 initial annual base salary, potential bonuses, and stock options but no severance benefits. Separately, Mitchell Cohen was named Interim CFO by the company through an agreement with InterimExecs beginning February 1, 2024, without additional benefits or severance, and can be terminated with a 30-day notice. Antonio Migliarese announced his resignation as CFO effective January 31, 2024, with his last day being February 15, 2024.
For further insights into CYDY corporate activity, check out TipRanks’ Insiders Trading Activity page.
